ClinicalTrials.Veeva

Menu

Fibroids and Infertility - a Study of the Significance of Removal of Fibroids With Regard to Endometrial Receptivity (FIN)

University of Oslo (UIO) logo

University of Oslo (UIO)

Status

Enrolling

Conditions

Leiomyoma, Uterine

Treatments

Procedure: Myomectomy per laparoscopy or laparotomy
Procedure: Transcervical resection of fibroids

Study type

Observational

Funder types

Other

Identifiers

NCT04426760
2017/9703

Details and patient eligibility

About

We aim to explore some of the molecular factors that reduce fertility for women with leiomyomas, taking into account leiomyoma location, size, number and vascularity. Tissue samples from the endometrium and leiomyomas will be obtained during the mid secretory phase before and 3-6 months after surgical excision for a comprehensive search for key molecular derangements.

Full description

Baseline medical information and standard questionnaire to record symptoms are collected from all participants and a gynaecological examination and a 2D and 3D vaginal ultrasonography including saline infusion sonography (SIS), if indicated, are performed. Blood samples for the biobank for extraction of germ line DNA and for identification of possible biomarkers are taken.

The women with submucosal leiomyomas will undergo hysteroscopic myomectomy and the women with intramural leiomyomas will undergo myomectomy per laparoscopy or laparotomy.

For the participants with intramural leiomyomas and the fertile/infertile controls, endometrial samples are taken with an endometrial suction curette in an outpatient setting at day 19-23 of the menstrual cycle. The endometrial sampling in the group of women with submucosal leiomyomas is being done during the hysteroscopic removal of the leiomyoma, also at day 19-23 of the menstrual cycle.

3-6 months after surgery, cycle day 19-23, endometrial samples will be taken from the women who have undergone myomectomy and ultrasound examination is being performed. The women with submucosal leiomyomas will undergo a second look hysteroscopy

Enrollment

80 estimated patients

Sex

Female

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age: 18 to 40 years
  • Presence of leiomyoma(s)
  • Regular menstrual cycle (28 +/- 7 days)
  • Having had at least 2 normal menstrual cycles after ending the treatment if previously treated with GnRH analogue
  • Signed informed consent

Exclusion criteria

  • No treatment indication (no symptoms and/or no desire for fertility)
  • Contraindication for surgery
  • Known endometriosis
  • Known PCOS
  • Untreated hydrosalpinx
  • Malignancy; gynaecological or other location
  • Pre-malignant or malignant pap smear or endometrial biopsy
  • Hormonal treatment including ulipristal acetat and levonorgestrel intrauterine device last three months before inclusion in the study
  • Ongoing treatment with GnRH analogue
  • Pregnancy last 3 months
  • Ongoing lactation

Trial design

80 participants in 4 patient groups

Women with submucosal leiomyoma(s)
Description:
Women with submucosal leimyomas undergoing hysteroscopical removal of the leiomyoma
Treatment:
Procedure: Transcervical resection of fibroids
Women with intramural leiomyomas
Description:
Women with intramural leiomyomas undergoing myomectomy
Treatment:
Procedure: Myomectomy per laparoscopy or laparotomy
Infertility patients
Description:
Patients treated at the Department for Reproductive Medicine at the Oslo University hospital failing to conceive after 3 or more embryo transfers with good quality embryos.
Fertile women
Description:
Healthy, volunteering women with proved fertility with 1 or more deliveries and no history of infertility

Trial contacts and locations

1

Loading...

Central trial contact

Thea F. Mikkelsen, MD; Kirsten Hald, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems